<SEC-DOCUMENT>0001387131-17-003644.txt : 20170717
<SEC-HEADER>0001387131-17-003644.hdr.sgml : 20170717
<ACCEPTANCE-DATETIME>20170717073244
ACCESSION NUMBER:		0001387131-17-003644
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170717
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170717
DATE AS OF CHANGE:		20170717

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		17966628

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>txmd-8k_071717.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 12pt; text-transform: none">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="1" STYLE="color: Black; width: 20%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; text-transform: uppercase; text-align: center">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 14pt">FORM
8-K</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SECURITIES
EXCHANGE ACT OF 1934<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
July 17, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 14pt"><B>TherapeuticsMD,
    Inc.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in
its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-00100</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>87-0233535</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or Other</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Jurisdiction of Incorporation)</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer</FONT><BR>
<FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">6800 Broken Sound Parkway NW, Third Floor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Boca Raton, FL 33487</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Office) (Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant's telephone number, including
area code: (561) 961-1900</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;&nbsp;&nbsp;&nbsp;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;&nbsp;&nbsp;&nbsp;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9744;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;&nbsp;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect; 230-405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&nbsp;&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &nbsp;&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 7.01</B></TD><TD STYLE="text-align: justify"><B>Regulation FD Disclosure.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 17, 2017, TherapeuticsMD,
Inc., a Nevada corporation (&ldquo;TherapeuticsMD&rdquo; or the &ldquo;Company&rdquo;), issued a press release announcing a regulatory
update regarding the New Drug Application (NDA) for TX-004HR, the Company's investigational applicator-free estradiol vaginal softgel
capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal
atrophy (VVA) due to menopause. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and
is incorporated in this Item 7.01 by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in
Items 7.01 and 9.01 of this Current Report on Form 8-K (including the exhibit) is furnished and shall not be deemed to be &ldquo;filed&rdquo;
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise
subject to the liabilities of that section. The information in Items 7.01 and 9.01 of this Current Report shall not be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the
date of this Current Report, regardless of any general incorporation language in the filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9.01.</B></TD><TD><B>Financial Statements and Exhibits.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Exhibits.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">                                                                                                                                                                                                                                                                                                                                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>Exhibit</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD><U>Number</U></TD><TD STYLE="text-align: justify"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1in">99.1</TD><TD STYLE="text-align: justify">Press Release from TherapeuticsMD, Inc., dated July 17, 2017, entitled &ldquo;TherapeuticsMD Provides
TX-004HR Regulatory Update.&rdquo;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.3pt 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 6pt"></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">Date: July 17, 2017</TD>
    <TD COLSPAN="2"><B>THERAPEUTICSMD, INC.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 44%">/s/ <I>Daniel A. Cartwright</I></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">Name:</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">Title:</P></TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Daniel A. Cartwright<BR>Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 243pt; text-align: center; text-indent: -243pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">                                                                                                                                                                                                                                                                                                                                                                                                                              <TR STYLE="vertical-align: top">
<TD>Exhibit</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><U>Number</U></TD><TD STYLE="text-align: justify"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 1in">99.1</TD><TD STYLE="text-align: justify">Press Release from TherapeuticsMD, Inc., dated July 17, 2017, entitled &ldquo;TherapeuticsMD Provides TX-004HR Regulatory Update.&rdquo;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: right; text-indent: -1.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><A HREF="txmd-8k_071717.htm">TherapeuticsMD, Inc. 8-K</A></P>

<P STYLE="margin: 0; text-align: right"><B><U>Exhibit 99.1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: right"><IMG SRC="txmd_logo.jpg" ALT=""></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR IMMEDIATE RELEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TherapeuticsMD Provides TX-004HR Regulatory
Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>BOCA RATON, Fla. </B>&ndash; <B>July
17, 2017</B> &ndash; TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women&rsquo;s healthcare company, today announced a regulatory
update regarding the New Drug Application (NDA) for TX-004HR, the company&rsquo;s investigational applicator-free estradiol vaginal
softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar
and vaginal atrophy (VVA) due to menopause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 14, 2017, the Company participated
in a Type A Post-Action Meeting with the Division of Bone, Reproductive, and Urologic Products (DBRUP) of the Food and Drug Administration
(FDA) to discuss the Complete Response Letter (CRL) that the Company previously received for the NDA for TX-004HR. The meeting
enabled the Company to present new information that the Company believes could address concerns raised by the FDA in the CRL and
positively affect the status of the NDA for TX-004HR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has received the minutes of
the meeting and, per the FDA&rsquo;s request, has formally submitted the new information for consideration related to the NDA for
TX-004HR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company continues to have a productive
dialogue with the FDA related to its review of this information but has not yet received a formal timeline from the FDA for a conclusion
of such review. The Company expects to have additional clarity on the pathway forward for the NDA for TX-004HR in the coming weeks.
The Company looks forward to working with the FDA to address its concerns regarding the NDA for TX-004HR and reserves the right
to pursue the FDA&rsquo;s formal dispute resolution process if a reasonable timeline to address such concerns cannot be established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About TherapeuticsMD, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TherapeuticsMD, Inc.&nbsp;is an innovative
healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA&trade; technology,&nbsp;TherapeuticsMD&nbsp;is
developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage
forms and administration routes. The company&rsquo;s late stage clinical pipeline includes two phase 3 product candidates: TX-001HR
for treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause and TX-004HR for treatment of moderate-to-severe
vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The company
also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD<SUP>&reg;</SUP> and BocaGreenMD<SUP>&reg;</SUP>
brands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><table style="width: 100%;" cellpadding="0" cellspacing="0"><tr><td style="width: 100%; text-align: center;">&nbsp;</td></tr></table></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release by TherapeuticsMD,
Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating
to TherapeuticsMD&rsquo;s objectives, plans and strategies as well as statements, other than historical facts, that address activities,
events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These
statements are often characterized by terminology such as &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;should,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;will,&rdquo; &ldquo;expects,&rdquo; &ldquo;estimates,&rdquo;
&ldquo;projects,&rdquo; &ldquo;positioned,&rdquo; &ldquo;strategy&rdquo; and similar expressions and are based on assumptions and
assessments made in light of management&rsquo;s experience and perception of historical trends, current conditions, expected future
developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the
date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of
new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject
to risks and uncertainties, many of which are outside of the company&rsquo;s control. Important factors that could cause actual
results, developments and business decisions to differ materially from forward-looking statements are described in the sections
titled &ldquo;Risk Factors&rdquo; in the company&rsquo;s filings with the Securities and Exchange Commission, including its most
recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following:
the company&rsquo;s ability to resolve the deficiencies identified by the FDA in the company&rsquo;s new drug application for its
TX-004HR product candidate and the time frame associated with such resolution; whether the company will be able to prepare an amended
NDA for its TX-004HR product candidate and, if prepared, whether the FDA will accept and approve the NDA; the company&rsquo;s ability
to maintain or increase sales of its products; the company&rsquo;s ability to develop and commercialize its hormone therapy drug
candidates and obtain additional financing necessary therefor; whether the company will be able to prepare an NDA for its TX-001HR
product candidate and, if prepared, whether the FDA will accept and approve the NDA; the length, cost and uncertain results of
the company&rsquo;s clinical trials, including any additional clinical trials that the FDA may require in connection with TX-004HR;
the potential of adverse side effects or other safety risks that could preclude the approval of the company&rsquo;s hormone therapy
drug candidates; the company&rsquo;s reliance on third parties to conduct its clinical trials, research and development and manufacturing;
the availability of reimbursement from government authorities and health insurance companies for the company&rsquo;s products;
the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading
price of the company&rsquo;s common stock and the concentration of power in its stock ownership. PDF copies of the company&rsquo;s
historical press releases and financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.35pt; text-indent: -5.35pt"><B><U>Investor Contact</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 292.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 292.3pt 0pt 0">David DeLucia</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 292.3pt 0pt 0">Director, Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 274.5pt 0pt 0">561-961-1900<BR>
David.DeLucia@TherapeuticsMD.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 274.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 274.5pt 0pt 0">&nbsp;</P>



<P STYLE="margin: 0; text-align: right"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: right"><B></B>

</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>txmd_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 txmd_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  K 1D# 2(  A$! Q$!_\0
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MQ'^SI)\4_B8OAG1O#2:W%J2Z@OVYY&AMY-C<;-N9CT7/ K]'?V%O^",GAO\
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MNBMX:O=5DO+RXTAHS&VE220ZD[6Y4@%3&24P0,;>@KC_ /@A)_P5.TC]ASX
MQ^$/B_INKZ!\._$NL7-WX8\7I923V(N0(UNK278"PVD(X(!(WG( (->IBHU[
M8E8;XKPVW^'6UNOIYGC8.>'YL(\7\*C/?;XE:]^G:^VA]%?\%G/^"5/P\^&_
M[,NI_&GX.Z!9?##XA?"UH]<BN?#B#3XKJ!)%\S=&F$61%)D5U 8["IR&XYC_
M (*3_P#!3KQ/KG_!$[X5>)-)U)M#\5?&]+?2-4U*V8Q_9$C1Q?LK+RF]X]AV
MC(21P.U2?\%4O^"MWA3]LGX0S_L^?LY?VC\3/&WQ.>+3+BYTZSE2VLK4NK2
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DK)8Z;#;L?Q10:Z.BBHE*4G>3N;4Z4*<>6FDEY:!1112-#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
